Asensus Surgical FY23 Unaudited Revenue Is Expected To Be Approximately $8.2M-$8.8M Versus Consensus Of $7.79M And Q4 Sales Of $5.1M-$5.7M Versus Consensus Of $4.67M
Portfolio Pulse from Benzinga Newsdesk
Asensus Surgical expects FY23 unaudited revenue of $8.2M-$8.8M, surpassing the consensus estimate of $7.79M. Q4 sales are projected to be $5.1M-$5.7M, also above the consensus of $4.67M. The company reported a 14% increase in global procedures to over 3,550 for the year and initiated eight Senhance Surgical Programs. As of December 31, 2023, Asensus had about $21.0 million in cash and short-term investments. In Q4, over 835 procedures were performed, and five new Senhance Programs were launched in various regions including Germany, Romania, the CIS region, and Japan.
January 08, 2024 | 11:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Asensus Surgical's FY23 revenue and Q4 sales projections exceed consensus estimates, with significant growth in global procedures and new program launches.
The positive revenue forecast exceeding consensus estimates, along with the growth in global procedures and the initiation of new surgical programs, is likely to be viewed favorably by investors. This could lead to increased investor confidence and a potential short-term uptick in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100